Cumate
Cumate is used as inducer in the Q-mate™ expression system.

QBI-HEK 293CymR Cells
QBI-HEK 293CymR cells stably express the repressor molecule CymR under the control of the CMV5 promoter which makes them ideal for application with the Q-mate™ inducible expression system. In addition, this cell line contains the E1A and E1B Adenovirus type 5 (Ad5) genes that complement these genes deleted in a recombinant Adenovirus.

Advantages

• Express stably the CymR repressor
• Grow easily
• Ideal for the generation of helper independent recombinant Adenovirus

Cumate Adenoviral Transfer Vectors
Based on the CymR approach, Qbiogene has also developed transfer vectors that can be used with our AdenoVator™ Adenoviral vector system.
Click here for more info.

Licensing Information

Q-mate™ Inducible Expression System
Use of the Q-mate™ Inducible Expression System (patent pending) is licensed to Qbiogene by the Biotechnology Research Institute, National Research Council of Canada. The technology is available through several options:

Academic Research Agreement: Q-mate™ Products are sublicensed to academic institution for research purposes only. Academic purchaser agrees that Products purchased will be used only at non-commercial institutions and only in research that is not sponsored by or pledged to be licensed to commercial entities. Commercial entities and non-profit organizations conducting research sponsored and/or in collaboration with commercial entities must refer to the Commercial Research Evaluation Agreement. No other rights are conveyed with the sale of the Products hereunder. Purchase of the Products does not convey any rights to (i) offer the vectors or any component, derivatives or modification thereof for resale, or (ii) distribute, transfer or otherwise provide access to, the Products or any component, derivative or modification thereof to any third party for any purpose or use.

Commercial Research Evaluation Agreement: Q-mate™ Products are sublicensed to commercial institutions for 6 month commercial evaluation purposes only. Commercial entities and non-profit organizations conducting research sponsored and/or in collaboration with commercial entities require a separate sub-license from Qbiogene after the 6 month Commercial Research Evaluation Agreement period. No other rights are conveyed with the sale of the Products hereunder. Purchase of the Products does not convey any rights to (i) offer the vectors or any component, derivatives or modification thereof for resale, or (ii) distribute, transfer or otherwise provide access to, the Products or any component, derivative or modification thereof to any third party for any purpose or use.

Commercial Research License Agreement: Following the 6 month Commercial Research Evaluation Agreement, commercial entities and non-profit organizations conducting research sponsored and/or in collaboration with commercial entities require a Commercial Research License Agreement from Qbiogene. A Commercial Research License Agreement does not convey any rights to (i) offer the vectors or any component, derivatives or modification thereof for resale, or (ii) distribute, transfer or otherwise provide access to, the Products or any component, derivative or modification thereof to any
third party for any purpose or use.

Clinical Development and Commercialization Agreement: Licenses can be obtained to allow clinical development and commercialization of a named product generated using the Q-mate™ Inducible Expression System. Users often continue to hold a Research Agreement when a license is in place, thus allowing them to continue to evaluate new products in the laboratory.

Services: Qbiogene can create Q-mate™ derived materials and manufacture research, GLP or cGMP grade product. The advantage of this approach is that Qbiogene brings extensive experience to the project.

Contact: For further licensing information, please contact the Manager of Business Development, Qbiogene Inc., 1801 de Maisonneuve West, Montreal, Quebec, Canada H3H 1J9 at 514-935-2200 or Q-mate@qbiogene.com.

CMV promoter
Use of the CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, Iowa 52242. A license to these patents for commercial use must be obtained directly from the University of Iowa Research Foundation. For further information, please contact UIRF at 319-335-4546.

CMV5 promoter
Use of the CMV5 promoter is covered under U.S. patent number 5,518,913 owned and licensed by the Biotechnology Research Institute (BRI), National Research Council of Canada, 6100 RoyalMount Avenue, Montreal, Quebec, Canada, H4P 2R2. Commercial and non-commercial research institutions are granted an automatic license with the purchase of this product to use the CMV5 promoter only for internal research purposes,
which license specifically excludes the right to sell, or otherwise transfer the CMV5 promoter or its component parts to third parties. A license to this patent for commercial use must be obtained directly from the BRI.

GFP
Use of the GFP is covered under U.S. patent number 6,027,881 owned and licensed by the National Institute of Health (NIH) and is restricted to the research market field. A license to this patent for commercial use must be obtained directly from the NIH, Office of Technology Transfer, Bethesda, MD 20892.

Use of the GFP is also covered under U.S. patent number 6,146,826 owned and licensed by Colombia University. Rights to use this product are limited to research use only; not for diagnostic or therapeutic use in humans or animals. No other rights are conveyed. Inquiry into the availability of a license to broader rights or the use of this product for commercial purposes should be directed to Columbia Innovation Enterprise, Columbia University, Engineering Terrace-Suite 363, Mail Code 2206, 500 West 120th Street, New York, New York 10027, USA.